» Articles » PMID: 34678196

Seroepidemiology and Model-based Prediction of SARS-CoV-2 in Ethiopia: Longitudinal Cohort Study Among Front-line Hospital Workers and Communities

Abstract

Background: Over 1 year since the first reported case, the true COVID-19 burden in Ethiopia remains unknown due to insufficient surveillance. We aimed to investigate the seroepidemiology of SARS-CoV-2 among front-line hospital workers and communities in Ethiopia.

Methods: We did a population-based, longitudinal cohort study at two tertiary teaching hospitals involving hospital workers, rural residents, and urban communities in Jimma and Addis Ababa. Hospital workers were recruited at both hospitals, and community participants were recruited by convenience sampling including urban metropolitan settings, urban and semi-urban settings, and rural communities. Participants were eligible if they were aged 18 years or older, had provided written informed consent, and were willing to provide blood samples by venepuncture. Only one participant per household was recruited. Serology was done with Elecsys anti-SARS-CoV-2 anti-nucleocapsid assay in three consecutive rounds, with a mean interval of 6 weeks between tests, to obtain seroprevalence and incidence estimates within the cohorts.

Findings: Between Aug 5, 2020, and April 10, 2021, we did three survey rounds with a total of 1104 hospital workers and 1229 community residents participating. SARS-CoV-2 seroprevalence among hospital workers increased strongly during the study period: in Addis Ababa, it increased from 10·9% (95% credible interval [CrI] 8·3-13·8) in August, 2020, to 53·7% (44·8-62·5) in February, 2021, with an incidence rate of 2223 per 100 000 person-weeks (95% CI 1785-2696); in Jimma Town, it increased from 30·8% (95% CrI 26·9-34·8) in November, 2020, to 56·1% (51·1-61·1) in February, 2021, with an incidence rate of 3810 per 100 000 person-weeks (95% CI 3149-4540). Among urban communities, an almost 40% increase in seroprevalence was observed in early 2021, with incidence rates of 1622 per 100 000 person-weeks (1004-2429) in Jimma Town and 4646 per 100 000 person-weeks (2797-7255) in Addis Ababa. Seroprevalence in rural communities increased from 18·0% (95% CrI 13·5-23·2) in November, 2020, to 31·0% (22·3-40·3) in March, 2021.

Interpretation: SARS-CoV-2 spread in Ethiopia has been highly dynamic among hospital worker and urban communities. We can speculate that the greatest wave of SARS-CoV-2 infections is currently evolving in rural Ethiopia, and thus requires focused attention regarding health-care burden and disease prevention.

Funding: Bavarian State Ministry of Sciences, Research, and the Arts; Germany Ministry of Education and Research; EU Horizon 2020 programme; Deutsche Forschungsgemeinschaft; and Volkswagenstiftung.

Citing Articles

Detection and comparison of SARS-CoV-2 antibody produced in naturally infected patients and vaccinated individuals in Addis Ababa, Ethiopia: multicenter cross-sectional study.

Bashea C, Gize A, Lejisa T, Bikila D, Zerihun B, Challa F Virol J. 2024; 21(1):192.

PMID: 39160532 PMC: 11334514. DOI: 10.1186/s12985-024-02443-6.


Tailoring COVID-19 Vaccination Strategies in High-Seroprevalence Settings: Insights from Ethiopia.

Gudina E, Elsbernd K, Yilma D, Kisch R, Wallrafen-Sam K, Abebe G Vaccines (Basel). 2024; 12(7).

PMID: 39066383 PMC: 11281643. DOI: 10.3390/vaccines12070745.


Seroprevalence of SARS-CoV-2 and Hepatitis B Virus Coinfections among Ethiopians with Acute Leukemia.

Alemu J, Gumi B, Tsegaye A, Rahimeto Z, Fentahun D, Ibrahim F Cancers (Basel). 2024; 16(8).

PMID: 38672687 PMC: 11049053. DOI: 10.3390/cancers16081606.


Long-term monitoring of SARS-CoV-2 seroprevalence and variants in Ethiopia provides prediction for immunity and cross-immunity.

Merkt S, Ali S, Gudina E, Adissu W, Gize A, Muenchhoff M Nat Commun. 2024; 15(1):3463.

PMID: 38658564 PMC: 11043357. DOI: 10.1038/s41467-024-47556-2.


Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study.

Banda L, Ho A, Kasenda S, Read J, Jewell C, Price A Int J Infect Dis. 2024; 137:118-125.

PMID: 38465577 PMC: 10695832. DOI: 10.1016/j.ijid.2023.10.020.


References
1.
Abdella S, Riou S, Tessema M, Assefa A, Seifu A, Blachman A . Prevalence of SARS-CoV-2 in urban and rural Ethiopia: Randomized household serosurveys reveal level of spread during the first wave of the pandemic. EClinicalMedicine. 2021; 35:100880. PMC: 8176122. DOI: 10.1016/j.eclinm.2021.100880. View

2.
Mulu A, Bekele A, Abdissa A, Balcha T, Habtamu M, Mihret A . The challenges of COVID-19 testing in Africa: the Ethiopian experience. Pan Afr Med J. 2021; 38:6. PMC: 7825374. DOI: 10.11604/pamj.2021.38.6.26902. View

3.
Alene M, Yismaw L, Assemie M, Ketema D, Mengist B, Kassie B . Magnitude of asymptomatic COVID-19 cases throughout the course of infection: A systematic review and meta-analysis. PLoS One. 2021; 16(3):e0249090. PMC: 7987199. DOI: 10.1371/journal.pone.0249090. View

4.
Peeling R, Wedderburn C, Garcia P, Boeras D, Fongwen N, Nkengasong J . Serology testing in the COVID-19 pandemic response. Lancet Infect Dis. 2020; 20(9):e245-e249. PMC: 7367660. DOI: 10.1016/S1473-3099(20)30517-X. View

5.
Gudina E, Gobena D, Debela T, Yilma D, Girma T, Mekonnen Z . COVID-19 in Oromia Region of Ethiopia: a review of the first 6 months' surveillance data. BMJ Open. 2021; 11(3):e046764. PMC: 8008954. DOI: 10.1136/bmjopen-2020-046764. View